Biblio Discovery — Demo Discovery Service

12 results for "Benjamin Besse"

Showing 1–12 · 0.23 seconds · RSS

  1. Journal Article Full text

    Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic Analysis

    David Planchard; Benjamin Besse; Harry J.M. Groen et al.

    Journal of Thoracic Oncology · 2021 · English · OpenAlex Scopus

    INTRODUCTION: Dabrafenib plus trametinib was found to have robust antitumor activity in patients with BRAF V600E-mutant metastatic NSCLC (mNSCLC). We report updated survival analysis of a phase 2 study (NCT01336634) with a minimum of 5-year follow-up and updated genomic data. METHODS: Pretreated…

  2. Journal Article Full text

    Sotorasib for Lung Cancers with KRAS p.G12C Mutation

    Ferdinandos Skoulidis; Bob T. Li; Grace Kho Dy et al.

    New England Journal of Medicine · 2021 · English · OpenAlex Scopus

    BACKGROUND: p.G12C-mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer activity was observed in a subgroup of patients with non-small-cell lung cancer (NSCLC). METHODS: p.G12C-mutated advanced NSCLC previously treated with standard therapies. The primary end…

  3. Journal Article Full text

    HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy

    Helena Alexandra Yu; Yasushi Goto; Hidetoshi Hayashi et al.

    Journal of Clinical Oncology · 2023 · English · OpenAlex Scopus

    PURPOSE Patritumab deruxtecan, or HER3-DXd, is an antibody-drug conjugate consisting of a fully human monoclonal antibody to human epidermal growth factor receptor 3 (HER3) attached to a topoisomerase I inhibitor payload via a stable tetrapeptide-based cleavable linker. We assessed the efficacy and…

  4. Journal Article Full text

    Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Edward Dela Cruz Drilon; D. Ross Camidge; W. Marston Linehan et al.

    New England Journal of Medicine · 2024 · English · OpenAlex Scopus

    The early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for the treatment of ROS1 fusion–positive non–small-cell lung cancer (NSCLC) have antitumor activity, but resistance develops in tumors, and intracranial activity is suboptimal. Repotrectinib is a next-generation ROS1 TKI…

  5. Journal Article Full text

    Amivantamab plus Lazertinib in Previously Untreated EGFR -Mutated Advanced NSCLC

    Byoung Chul Cho; Shun Lu; Enriqueta Felip et al.

    New England Journal of Medicine · 2024 · English · OpenAlex Scopus

    Background Amivantamab plus lazertinib (amivantamab–lazertinib) has shown clinically meaningful and durable antitumor activity in patients with previously untreated or osimertinib-pretreated EGFR (epidermal growth factor receptor)–mutated advanced non–small-cell lung cancer (NSCLC). Methods In a…

  6. Journal Article Full text

    Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

    Alexander Edward Dela Cruz Drilon; Geoffrey R. Oxnard; Daniel Shao-Weng Tan et al.

    New England Journal of Medicine · 2020 · English · OpenAlex Scopus

    BACKGROUND: fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. METHODS: fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point…